ArticleMolecular genetics & genomic medicine2021
Investigating the ACE2 polymorphisms in COVID-19 susceptibility: An in silico analysis.
Article in Molecular genetics & genomic medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 41 citations in OpenAlex.
- Association of angiotensin-converting enzyme 2 gene polymorphisms with hypertension and treatment response to hydroxychloroquine in Iranian people with coronavirus disease 2019: A cross-sectional study.The Journal of international medical research · 2025Article
- Genetic Predictors of Paxlovid Treatment Response: The Role of IFNAR2, OAS1, OAS3, and ACE2 in COVID-19 Clinical Course.Journal of personalized medicine · 2025Article
- Genetically edited human placental organoids cast new light on the role of ACE2.Cell death & disease · 2025Article
- Serpentoviruses Exhibit Diverse Organization and ORF Composition with Evidence of Recombination.Viruses · 2024Article
- Genomic insight into COVID-19 severity in MAFLD patients: a single-center prospective cohort study.Frontiers in genetics · 2024Article
- Role ofAfrican journal of laboratory medicine · 2024Article
- Genetic Predictors of Comorbid Course of COVID-19 and MAFLD: A Comprehensive Analysis.Viruses · 2023Review
- Impacts of SARS-CoV-2 on diabetes mellitus: A pre and post pandemic evaluation.World journal of virology · 2023Review
- Angiotensin-converting enzyme 2 (ACE2) polymorphisms and susceptibility of severe SARS-CoV-2 in a subset of Pakistani population.Virology journal · 2023Article
- Genetic Variants within SARS-CoV-2 Human Receptor Genes May Contribute to Variable Disease Outcomes in Different Ethnicities.International journal of molecular sciences · 2023Review
- Single Nucleotide Variants (SNVs) of Angiotensin-Converting Enzymes (ACE1 and ACE2): A Plausible Explanation for the Global Variation in COVID-19 Prevalence.Journal of the renin-angiotensin-aldosterone system : JRAAS · 2023Review
- Characterization of the angiotensin-converting enzyme 2 (ACE2), the main receptor for the SARS-CoV-2 virus.American journal of clinical and experimental immunology · 2023Review
- ACE2 polymorphisms impact COVID-19 severity in obese patients.Scientific reports · 2022Article
- Association of ACE2 Gene Variants with the Severity of COVID-19 Disease-A Prospective Observational Study.International journal of environmental research and public health · 2022Observational
- Most frequently harboured missense variants of hACE2 across different populations exhibit varying patterns of binding interaction with spike glycoproteins of emerging SARS-CoV-2 of different lineages.Computers in biology and medicine · 2022Article
- SNPs of ACE1 (rs4343) and ACE2 (rs2285666) genes are linked to SARS-CoV-2 infection but not with the severity of disease.Virology journal · 2022Article
- Article
- Genetic Predisposition and Inflammatory Inhibitors in COVID-19: Where Do We Stand?Biomedicines · 2022Review
- An update on angiotensin-converting enzyme 2 structure/functions, polymorphism, and duplicitous nature in the pathophysiology of coronavirus disease 2019: Implications for vascular and coagulation disease associated with severe acute respiratory syndrome coronavirus infection.Frontiers in microbiology · 2022Review
- The association ofEXCLI journal · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNovel coronavirus (SARS-CoV-2) became an epidemic disease and lead to a pneumonia outbreak first in December 2019 in Wuhan, China. The symptoms related to coronavirus disease-19 (COVID-19) were different ranging from mild to severe lung injury and multi-organ failure symptoms, eventually leading to death, especially in older patients with other co-morbidities. The receptor of this virus in the human cell is angiotensin-converting enzyme 2 (ACE2).
methodsIn this paper, we aimed to perform an in silico analysis of the frequently studied variants of the ACE2 gene and determine the effects of the variants in mRNA secondary structure and binding affinity of cellular factors. Fourteen single-nucleotide polymorphisms were selected based on previous studies and investigated.
resultsAll of the variants were analyzed in the RNAsnp database and three revealed a significant p-value. The spliceAid2 database prediction showed that 7 out of 14 SNPs caused an alteration in a way that only the wild or mutated form was able to bind to proteins. The latter database also reported that three SNPs produces a dual form in which different specific proteins can bind to the sequence in a specific form (either wild or mutated form).
conclusionAltogether, these estimations revealed the potential of variants in manipulation of the final stable form of ACE2 that can lead to different COVID-19 susceptibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.